Skip to main content

Advertisement

SpringerLink
Log in

Complications of Immunosuppressive/Immunomodulatory Therapy in Neurological Diseases

  • Neuroimmunology (R Lisak, Section Editor)
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

The first critical step in the appropriate treatment of neurological infectious disease accompanying immunosuppressive states or immunomodulatory medication is to properly identify the offending organism. Broadly immunosuppressive conditions will predispose to both common and uncommon infectious diseases. There are substantial differences between neurological infectious disorders complicating disturbances of the innate immunity (neutrophils, monocytes and macrophages) and those due to abnormal adaptive immunity (humoral and cellular immunity). Similarly, there are differences in the types of infections with impaired humoral immunity compared to disturbed cellular immunity and between T- and B-cell disorders. HIV/AIDS has been a model of acquired immunosuppression and the nature of opportunistic infections with which it has been associated has been well characterized and generally correlates well with the degree of CD4 lymphopenia. Increasingly, immunotherapies target specific components of the immune system, such as an adhesion molecule or its ligand or surface receptors on a special class of cells. These targeted perturbations of the immune system increase the risk of particular infectious diseases. For instance, natalizumab, an α4β1 integrin inhibitor that is highly effective in multiple sclerosis, increases the risk of progressive multifocal leukoencephalopathy for reasons that still remain unclear. It is likely that other therapies that result in a disruption of a specific component of the immune system will be associated with other unique opportunistic infections. The risk of multiple simultaneous neurological infections in the immunosuppressed host must always be considered, particularly with a failure to respond to a therapeutic regimen. With respect to appropriate and effective therapy, diagnostic accuracy assumes primacy, but occasionally broad spectrum therapy is necessitated. For a number of opportunistic infectious disorders, particularly some viral and fungal diseases, antimicrobial therapy remains inadequate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Berger JR. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf. 2010;33(11):969–83. This article addresses the risk of PML with the newer biological agents and describe potential mechanisms by which these therapies may predispose to the development of this disorder.

    Article  PubMed  CAS  Google Scholar 

  2. Fox R. Advances in the management of PML: focus on natalizumab. Cleve Clin J Med. 2011;78 Suppl 2:S33–7.

    Article  PubMed  Google Scholar 

  3. Khatri BO, Man S, Giovannoni G, Koo AP, Lee JC, Tucky B, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology. 2009;72(5):402–9.

    Article  PubMed  CAS  Google Scholar 

  4. BiogenIdec (2011) Tysabri Update. https://medinfo.biogenidec.com. Accessed January 7, 2012.

  5. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010;9(4):438–46. This is an excellent description of the first cases of natalizumab-associated PML focusing on the clinical and radiographic manifestations and demonstrating a high rate of concomitant IRIS

    Article  PubMed  CAS  Google Scholar 

  6. Tan IL, McArthur JC, Clifford DB, Major EO, Nath A. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2011;77(11):1061–7.

    Article  PubMed  CAS  Google Scholar 

  7. Hartung HP, Berger JR, Wiendl H, Meier U, Stangel M, Aktas O, et al. Therapie der Multiplen Sklerose mit monokonalen Antikorpen: aktualisierte Empfelungen im Rahmen eines Expertmeetings. Actuelle Neurologie. 2011;38:2–11.

    Article  Google Scholar 

  8. Hou J, Major EO. The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J Neurovirol. 1998;4(4):451–6.

    Article  PubMed  CAS  Google Scholar 

  9. Kerr DA, Chang CF, Gordon J, Bjornsti MA, Khalili K. Inhibition of human neurotropic virus (JCV) DNA replication in glial cells by camptothecin. Virology. 1993;196(2):612–8.

    Article  PubMed  CAS  Google Scholar 

  10. Brickelmaier M, Lugovskoy A, Kartikeyan R, Reviriego-Mendoza MM, Allaire N, Simon K, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother. 2009;53(5):1840–9.

    Article  PubMed  CAS  Google Scholar 

  11. Andrei G, Snoeck R, Vandeputte M, De Clercq E. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother. 1997;41(3):587–93.

    PubMed  CAS  Google Scholar 

  12. Hall CD, Dafni U, Simpson D, Clifford D, Wetherill PE, Cohen B, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS clinical trials group 243 team. N Engl J Med. 1998;338(19):1345–51.

    Article  PubMed  CAS  Google Scholar 

  13. Gasnault J, Kousignian P, Kahraman M, Rahoiljaon J, Matheron S, Delfraissy JF, et al. Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring. J Neurovirol. 2001;7(4):375–81.

    Article  PubMed  CAS  Google Scholar 

  14. Marra CM, Rajicic N, Barker DE, Cohen BA, Clifford D, Donovan Post MJ, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS. 2002;16(13):1791–7.

    Article  PubMed  CAS  Google Scholar 

  15. Mori Y, Miyamoto T, Nagafuji K, Kamezaki K, Yamamoto A, Saito N, et al. High incidence of human herpes virus 6-associated encephalitis/myelitis following a second unrelated cord blood transplantation. Biol Blood Marrow Transplant. 2010;16(11):1596–602.

    Article  PubMed  Google Scholar 

  16. Razonable RR. Infections due to human herpesvirus 6 in solid organ transplant recipients. Curr Opin Organ Transplant. epub before print.

  17. Baldwin K. Ganciclovir-resistant human herpesvirus-6 encephalitis in a liver transplant patient: a case report. J Neurovirol. 2011;17(2):193–5.

    Article  PubMed  Google Scholar 

  18. Takahashi Y, Yamada M, Nakamura J, Tsukazaki T, Padilla J, Kitamura T, et al. Transmission of human herpesvirus 7 through multigenerational families in the same household. Pediatr Infect Dis J. 1997;16(10):975–8.

    Article  PubMed  CAS  Google Scholar 

  19. Erice A, Tierney C, Hirsch M, Caliendo AM, Weinberg A, Kendall MA, et al. Cytomegalovirus (CMV) and human immunodeficiency virus (HIV) burden, CMV end-organ disease, and survival in subjects with advanced HIV infection (AIDS clinical trials group protocol 360). Clin Infect Dis. 2003;37(4):567–78.

    Article  PubMed  CAS  Google Scholar 

  20. Clarke LM, Duerr A, Feldman J, Sierra MF, Daidone BJ, Landesman SH. Factors associated with cytomegalovirus infection among human immunodeficiency virus type 1-seronegative and -seropositive women from an urban minority community. J Infect Dis. 1996;173(1):77–82.

    Article  PubMed  CAS  Google Scholar 

  21. Silva CA, Oliveira AC, Vilas-Boas L, Fink MC, Pannuti CS, Vidal JE. Neurologic cytomegalovirus complications in patients with AIDS: retrospective review of 13 cases and review of the literature. Rev Inst Med Trop Sao Paulo. 2011;52(6):305–10. This is an excellent review of CMV infection in the setting of HIV/AIDS.

    Google Scholar 

  22. Reddy SM, Winston DJ, Territo MC, Schiller GJ. CMV central nervous system disease in stem-cell transplant recipients: an increasing complication of drug-resistant CMV infection and protracted immunodeficiency. Bone Marrow Transplant. 2010;45(6):979–84.

    Article  PubMed  CAS  Google Scholar 

  23. Akpek G, Mikulski M, Kleinberg M, Badros A, Yanovich S, Rapoport AP. Cellular therapy with sequential unmanipulated donor lymphocyte infusions in drug-resistant cytomegalovirus (CMV) encephalitis. Blood. 2011;117(21):5772–4.

    Article  PubMed  CAS  Google Scholar 

  24. Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM, et al. Adoptive transfer of pp 65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood. 2010;116(20):4360–7.

    Article  PubMed  CAS  Google Scholar 

  25. Grover D, Newsholme W, Brink N, Manji H, Miller R. Herpes simplex virus infection of the central nervous system in human immunodeficiency virus-type 1-infected patients. Int J STD AIDS. 2004;15(9):597–600.

    Article  PubMed  CAS  Google Scholar 

  26. Solomon T, Michael BD, Smith PE, Sanderson F, Davies NW, Hart IJ, et al. National guideline for the management of suspected viral encephalitis in adults. J Infect. epub before print.

  27. Dennett C, Klapper PE, Cleator GM. Polymerase chain reaction in the investigation of “relapse” following herpes simplex encephalitis. J Med Virol. 1996;48(2):129–32.

    Article  PubMed  CAS  Google Scholar 

  28. NIAID Collaborative Antiviral Study Group. Long term treatment of herpes simplex encephalitis (HSE) with Valtrex [cited 2012 January 12].

  29. Kamei S, Sekizawa T, Shiota H, Mizutani T, Itoyama Y, Takasu T, et al. Evaluation of combination therapy using aciclovir and corticosteroid in adult patients with herpes simplex virus encephalitis. J Neurol Neurosurg Psychiatry. 2005;76(11):1544–9.

    Article  PubMed  CAS  Google Scholar 

  30. Martinez-Torres F, Menon S, Pritsch M, Victor N, Jenetzky E, Jensen K, et al. Protocol for German trial of acyclovir and corticosteroids in herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial [ISRCTN45122933]. BMC Neurol. 2008;8:40.

    Article  PubMed  Google Scholar 

  31. De Broucker T, Mailles A, Chabrier S, Morand P and Stahl JP. Acute varicella zoster encephalitis without evidence of primary vasculopathy in a case-series of 20 patients. Clin Microbiol Infect 2011. doi:10.111/j.1469.2011.03705.x.

  32. Schweikert A, Kremer M, Ringel F, Liebig T, Duyster J, Stuve O, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol. 2009;66(3):403–6.

    Article  PubMed  CAS  Google Scholar 

  33. Finelli PF, Naik K, DiGiuseppe JA, Prasad A. Primary lymphoma of CNS, mycophenolate mofetil and lupus. Lupus. 2006;15(12):886–8.

    Article  PubMed  CAS  Google Scholar 

  34. Svobodova B, Hruskova Z, Rysava R and Tesar V. Brain diffuse large B-cell lymphoma in a systemic lupus erythematosus patient treated with immunosuppressive agents including mycophenolate mofetil. Lupus. 2011;20(13):1452–4.

    Google Scholar 

  35. Gonzalez-Aguilar A, Soto-Hernandez JL. The management of primary central nervous system lymphoma related to AIDS in the HAART era. Curr Opin Oncol. 2011;23(6):648–53.

    Article  PubMed  CAS  Google Scholar 

  36. Carrabba MG, Reni M, Foppoli M, Chiara A, Franzin A, Politi LS, et al. Treatment approaches for primary CNS lymphomas. Expert Opin Pharmacother. 2010;11(8):1263–76.

    Article  PubMed  CAS  Google Scholar 

  37. Batchelor TT, Grossman SA, Mikkelsen T, Ye X, Desideri S, Lesser GJ. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology. 2011;76(10):929–30.

    Article  PubMed  CAS  Google Scholar 

  38. Lai GG, Koo YX, Tao M, Tan TT, Lim ST. Use of rituximab in combination with high-dose methotrexate in the treatment of primary central nervous system lymphoma in a mycophenolate mofetil treated patient with lupus nephritis. Acta Oncol. 2010;50(1):144–5.

    Article  PubMed  Google Scholar 

  39. Algazi AP, Kadoch C, Rubenstein JL. Biology and treatment of primary central nervous system lymphoma. Neurotherapeutics. 2009;6(3):587–97.

    Article  PubMed  CAS  Google Scholar 

  40. Chaudhuri A, Martinez-Martin P, Kennedy PG, Andrew Seaton R, Portegies P, Bojar M, et al. EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS task force on acute bacterial meningitis in older children and adults. Eur J Neurol. 2008;15(7):649–59.

    Article  PubMed  CAS  Google Scholar 

  41. Mitja O, Pigrau C, Ruiz I, Vidal X, Almirante B, Planes AM, et al. Predictors of mortality and impact of aminoglycosides on outcome in listeriosis in a retrospective cohort study. J Antimicrob Chemother. 2009;64(2):416–23.

    Article  PubMed  CAS  Google Scholar 

  42. Matano S, Satoh S, Harada Y, Nagata H and Sugimoto T. Antibiotic treatment for bacterial meningitis caused by Listeria monocytogenes in a patient with multiple myeloma. J Infect Chemother. 2011;16(2):123–5.

    Google Scholar 

  43. Singh JA, Wells GA, Christensen R, Tanjong E, Maxwell GL, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2:CD008794. This article is a valuable review of the complications observed with biological agents.

    PubMed  Google Scholar 

  44. Garg RK. Tuberculous meningitis. Acta Neurol Scand. 2010;122(2):75–90.

    PubMed  CAS  Google Scholar 

  45. Girgis NI, Farid Z, Kilpatrick ME, Sultan Y, Mikhail IA. Dexamethasone adjunctive treatment for tuberculous meningitis. Pediatr Infect Dis J. 1991;10(3):179–83.

    Article  PubMed  CAS  Google Scholar 

  46. Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics. 1997;99(2):226–31.

    Article  PubMed  CAS  Google Scholar 

  47. Berger JR. Immunodeficiency states. In: Noseworthy J, editor. Neurological therapeutics principles and practice. Oxon: Informa Healthcare; 2006. p. 1540–57.

    Google Scholar 

Download references

Disclosure

A. Nath: none. J.R Berger is a consultant for Millennium (Data Safety Monitoring Board), Biogen, Novartis, Bayer, Genzyme, Eisai, Genentech, and Amgen (Data Safety Monitoring Board); has received a grant from the PML Consortium; an honorarium from PRIME; and speaking fees from Novartis.

Author information

Authors and Affiliations

  1. Department of Neurology, University of Kentucky College of Medicine, Kentucky Clinic L-445, 740 S. Limestone Street, Lexington, KY, 40536-0284, USA

    Avindra Nath MB BS, FAAN & Joseph R. Berger MD, FAAN, FACP

Authors
  1. Avindra Nath MB BS, FAAN
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph R. Berger MD, FAAN, FACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph R. Berger MD, FAAN, FACP.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nath, A., Berger, J.R. Complications of Immunosuppressive/Immunomodulatory Therapy in Neurological Diseases. Curr Treat Options Neurol 14, 241–255 (2012). https://doi.org/10.1007/s11940-012-0172-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-012-0172-y

Keywords

Search

Navigation